NasdaqCM:PLSEMedical Equipment
Pulse Biosciences (PLSE) Is Up 70.4% After Strong First-in-Human nPulse AF Data Release – Has The Bull Case Changed?
In early February 2026, Pulse Biosciences reported late-breaking first-in-human data for its nPulse Cardiac Catheter, showing high atrial fibrillation treatment success, short procedure times, and a low rate of serious adverse events, presented at the 31st Annual AF Symposium in Boston.
The early 6- and 12-month outcomes, including very high procedural success in evaluable patients, highlight how nanosecond pulse field ablation may become a differentiated option within catheter-based atrial...